Equity Overview
Price & Market Data
Price: $1.14
Daily Change: $0.00 / 0.00%
Range: $1.10 - $1.16
Market Cap: $69,356,544
Volume: 87,742
Performance Metrics
1 Week: 6.54%
1 Month: 8.57%
3 Months: -6.56%
6 Months: -49.33%
1 Year: -56.49%
YTD: -33.72%
Company Details
Employees: 61
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.